Skip to main content
Log in

Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-α blockade

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Chronic inflammation in ankylosing spondylitis (AS) is associated with vascular endothelial dysfunction. Infliximab improves inflammatory disease activity in AS patients, but its effect on endothelial dysfunction has still not been tested in these patients. Twelve anti-TNF naive AS patients (mean age, 32.6 ± 3.94 years; disease duration, 5.6 ± 0.8 years) with high disease activity [Bath ankylosing spondylitis disease activity index (BASDAI score > 4)] despite treatment with stable doses of conventional disease modifying anti-rheumatic drugs (DMARDs) were investigated. Inflammatory disease activity [BASDAI and Bath ankylosing spondylitis functional index (BASFI) scores, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels], serum nitrite concentration, and endothelium-dependent and endothelium-independent vasodilation of the brachial artery were measured at baseline and 12 weeks of therapy after single intravenous infusion of infliximab (5 mg/kg). Previous DMARD(s) regimen remained unchanged throughout the study period. After treatment with infliximab, flow-mediated vasodilation improved from 9.81 ± 1.70% to 26.93 ± 2.34% (p < 0.001), whereas there was no significant change in endothelium-independent vasodilation with nitroglycerin and baseline diameter (13.65 ± 2.10% versus 14.59 ± 1.93%, p = 0.08, and 4.45 ± 0.15 versus 4.46 ± 0.15 mm, p = 0.3, respectively). Nitrite concentration reduced from 6.50 ± 0.21 to 2.57 ± 0.18 µmol/l (p < 0.001), ESR from 40.90 ± 6.00 to 11.50 ± 1.38 mm in the first hour (p < 0.001), and CRP level from 29.08 ± 4.11 to 2.69 ± 0.43 mg/dl (p < 0.001). BASDAI and BASFI scores were significantly reduced from 5.40 ± 1.14 to 1.40 ± 0.70 (p < 0.05) and 5.05 ± 1.76 to 0.20 ± 0.63 (p < 0.05), respectively. The study suggests that in ankylosing spondylitis, endothelial dysfunction is a part of the disease process and infliximab improves both endothelial dysfunction and inflammatory disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Agarwal V (2010) Spondyloarthropathies. In: Syngle A, Deodhar SD (eds) Rheumatology principles and practice. Jaypee, India, pp 179–189

    Google Scholar 

  2. Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M et al (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45:283–286

    Article  CAS  PubMed  Google Scholar 

  3. Lautermann D, Barun J (2002) Ankylosing spondylitis—cardiac manifestations. Clin Exp Rheumatol 20:S11–S15

    CAS  PubMed  Google Scholar 

  4. Lehtinen K (1993) Mortality and causes of death in 398 patients admitted with ankylosing spondylitis. Ann Rheum Dis 52:174–176

    Article  CAS  PubMed  Google Scholar 

  5. Peters MJ, Irene E, Horst-Bruinsma V et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592

    Article  PubMed  Google Scholar 

  6. Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 09:171–176

    Google Scholar 

  7. Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19:358–362

    Article  PubMed  Google Scholar 

  8. Van Ejick IC, Peters MJL, Seme EH, van der Horst-bruinsma IE, Dijkmans BAC, Smulders YM, Nurmohamed MT (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis 66:362–366

    Google Scholar 

  9. Gonzalez-Gay MA, Gonzalez Juananey C, Martin J (2005) Rheumatoid arthritis; a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8–17

    Article  PubMed  Google Scholar 

  10. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammantano L, Simantov R et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406

    Article  CAS  PubMed  Google Scholar 

  11. Poddubnyĭ DA, Rebrov AP (2007) Endothelial dysfunction in patients with Bechterew’s disease (ankylosing spondylitis). Klin Med (Mosk) 85:66–69

    Google Scholar 

  12. Bilsborough W, Keen H, Taylor A, O’Driscoll GJ, Arnolda L, Green DJ (2006) Anti tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26:1125–1131

    Article  CAS  PubMed  Google Scholar 

  13. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D et al (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35

    Article  CAS  PubMed  Google Scholar 

  14. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 09:III27–32

    Google Scholar 

  15. Blake GJ, Ridker PM (2001) Novel clinical markers of vascular wall inflammation. Circ Res 89:763–771

    Article  CAS  PubMed  Google Scholar 

  16. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al (2002) Anti-tumour necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187

    Article  PubMed  Google Scholar 

  17. Zochling J (2008) Assessment and treatment of ankylosing spondylitis: current status and future directions. Current Opinion in Rheumatology 20:398–403

    Article  PubMed  Google Scholar 

  18. Syngle A (2006) Arthritis and its treatment. In: Rattan S, Kassem M (eds) Prevention and treatment of age-related diseases. Springer, the Netherlands, pp 105–32

    Chapter  Google Scholar 

  19. Braun J, Brandt J, Listing A, Zink R, Alten G, Burmester W, Golder E et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis & Rheumatism 48:2224–2233

    Article  CAS  Google Scholar 

  20. Cardillo C, Schinzari F, Mores N et al (2006) Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 80:275–281

    Article  CAS  PubMed  Google Scholar 

  21. Booth AD, Jayne DR, Kharbanda RK et al (2004) Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109:1718–1723

    Article  CAS  PubMed  Google Scholar 

  22. Schinzari F, Armuzzi A, De Pascalis B et al (2008) Tumor necrosis factor-α antagonism improves endothelial dysfunction in patients with Crohn’s disease. Clin Pharmacol Ther 83:70–76

    Article  CAS  PubMed  Google Scholar 

  23. Vander LS, Valkerburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368

    Article  Google Scholar 

  24. Zochling J, Braun J, van der Heijde D (2007) Assessments in ankylosing spondylitis. Best Practice & Research Clinical Rheumatology 21:699–712

    Article  Google Scholar 

  25. Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS (2002) Spectrophotometric determination of serum nitrite and nitrate by copper–cadmium alloy. Anal Biochem 306:79–82

    Article  CAS  PubMed  Google Scholar 

  26. Wanchu A, Khullar M, Sud A, Bambrey P (1999) Nitric oxide production is increased in patients with inflammatory myositis. Nitric oxide 3:454–458

    Article  CAS  PubMed  Google Scholar 

  27. Himento M, Ishibashi T, Nakano S, Furuya K, Kigoshi T, Uchida K et al (2003) A practical procedure for achieving a steady state of NO x concentration in plasma: with special reference to NO x content of Japanese daily food. Tohoku J Exp Med 199:95–110

    Article  Google Scholar 

  28. Zochling J, Braun J, van der Heijde D (2006) Assessments in ankylosing spondylitis. Best Practice & Research Clinical Rheumatology 20:521–537

    Article  Google Scholar 

  29. Karoli NA, Rebrov AP (2007) Vascular wall lesion and disorder of endothelial vasoregulating function in patients with ankylosing spondylitis. Klin Med (Mosk) 85:54–57

    CAS  Google Scholar 

  30. Caliskan M, Erdogan D, Gullu H et al (2008) Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 196:306–312

    Article  CAS  PubMed  Google Scholar 

  31. Mathieu S, Joly H, Baron G, Tournadre G, Dubost J-J, Ristori JM (2008) Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 47:1203–7

    Article  CAS  Google Scholar 

  32. Syngle A, Vohra K, Kaur L, Sharma S (2009) Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scand J Rheumatol 38:15–22

    Article  CAS  PubMed  Google Scholar 

  33. Cardaropoli S, Silvango F, Morra E, Pescarmona GP, Tordos T (2003) Infectious and inflammatory stimuli decrease endothelial nitric oxide synthase activity in vitro. J Hypertens 21:2103–2110

    Article  CAS  PubMed  Google Scholar 

  34. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME (1993) Tumor necrosis factor down regulates an endothelial nitric oxide synthase mRNA by shortening its half life. Circ Res 73:205–209

    CAS  PubMed  Google Scholar 

  35. Vita JA, Keaney JF Jr, Larson MG, Keyes MJ, Massaro JM, Lipinska I et al (2004) Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 110:3604–3609

    Article  CAS  PubMed  Google Scholar 

  36. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Mäkimattila S, Taskinen MR, Yki-Järvinen H (2002) Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 22:1637–1641

    Article  CAS  PubMed  Google Scholar 

  37. Koppenol WH et al (1992) Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol 5:834–842

    Article  CAS  PubMed  Google Scholar 

  38. Sierksma A, van der Gaag MS, Grobbee DE, Hendriks HF (2003) Acute and chronic effects of dinner with alcoholic beverages on nitric oxide metabolites in healthy men. Clin Exp Pharmacol Physiol 30:504–506

    Article  CAS  PubMed  Google Scholar 

  39. Kumar A, Falodia SK, Shankar S, Grover R, Marwaha V, Aneja R, Srivastava K, Das N (2009) Assessment of serum nitrite as biomarker of disease activity in ankylosing spondylitis. Indian J Rheumatology 4:47–50

    Article  Google Scholar 

  40. Sari I, Kebapcilar L, Alacacioglu A, Bilgir O, Yildiz Y, Taylan A (2009) Increased levels of asymmetric dimethylarginine (ADMA)in patients with ankylosing spondylitis. Inter Med 48:1363–1368

    Article  Google Scholar 

  41. Boger RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38:126–136

    Article  PubMed  CAS  Google Scholar 

  42. Boger RH, Maas R, Schulze F, Schwedhelm E (2005) Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 43:1124–1129

    Article  PubMed  CAS  Google Scholar 

  43. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA (2006) Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:921–933

    CAS  PubMed  Google Scholar 

  44. Popa C, Netea MG, Radstake T et al (2005) Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64:303–5

    Article  CAS  PubMed  Google Scholar 

  45. Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH et al (2007) Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66:764–70

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Support and acknowledgment: None.

Disclosures

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ashit Syngle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Syngle, A., Vohra, K., Sharma, A. et al. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-α blockade. Clin Rheumatol 29, 763–770 (2010). https://doi.org/10.1007/s10067-010-1402-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1402-x

Keywords

Navigation